Founded by Dr. Jack Rubinstein as Chief Medical Officer TRPV Pharmaceuticalsa company dedicated to advancing therapeutic approaches for cardiovascular disease.

Rubinstein is also a professor of internal medicine at the University of California School of Medicine and a pioneering researcher in the field of cardiovascular disease.

Through more than a decade of intense research, Rubinstein discovered some surprising new facts:

• An FDA-approved drug originally designed to manage gout, known as probenecid, has significantly reduced the lives of heart disease patients who suffer from reduced cardiac output and reduced heart contractility, a condition known as heart failure. There is a possibility that it can be reused to improve.

Rubinstein shared situations in which the heart muscle is unable to pump blood effectively, which can lead to circulatory failure.

Partnering with Fred Sexton, a seasoned entrepreneurial executive in the pharmaceutical industry with experience developing successful startups, the two co-founded TRPV Pharmaceuticals.

Mr. Sexton is the CEO of TRPV Pharmaceuticals and said, “The company’s launch is centered on advances in transient receptor potential vanilloid (TRPV) channel agonist-based therapies, and primarily “We focus on probenecid, a substance found in gout medications and its active ingredient.” Currently under development. ”